Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HOUSTON, May 28, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the following conferences.
Greg Browne, Cyberonics’ Chief Financial Officer, will present at the Jefferies 2013 Global Healthcare Conference in New York on Thursday, June 6, 2013 at 9:00 AM Eastern Time. A live audio webcast of the presentation can be accessed by clicking on the Investor Relations link on the Cyberonics home page at http://www.cyberonics.com on June 6, 2013.
Mr. Browne, along with Milton Morris, Ph.D., Cyberonics’ Senior Vice President, Research and Development, and Sherrie Perkins, Cyberonics’ Vice President of Marketing and New Business Development, will present at the William Blair 33rd Annual Growth Stock Conference in Chicago on Tuesday, June 11, 2013 at 10:10 AM Central Time. A live audio webcast of the presentation can be accessed by clicking on the Investor Relations link on the Cyberonics home page at http://www.cyberonics.com on June 11, 2013.
In addition, Mr. Browne and Ms. Perkins will present at the Goldman Sachs 34th Annual Global Healthcare Conference in Rancho Palos Verdes on June 12, 2013 at 1:20 PM Pacific Time. A live audio webcast of the presentation can be accessed by clicking on the Investor Relations link on the Cyberonics home page at http://www.cyberonics.com on June 12, 2013.
Finally, Mr. Browne, along with Peter Donato, Cyberonics’ Corporate Controller, will participate in the Northcoast Research 2013 Healthcare Forum in New York on Tuesday, June 18, 2013. The format for this conference is one-on-one or small group meetings. No formal presentation will be made, and the group meetings will not be webcast.
About Cyberonics, Inc. and the VNS Therapy® System
Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.
Contact Information
Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main: (281) 228-7262 / Fax: (281) 218-9332
ir@cyberonics.com
SOURCE Cyberonics, Inc.
Help employers find you! Check out all the jobs and post your resume.
